Leadership Team

Mr. Voigt has served as CEO and Executive Director of Immutep since July 2014. He has over 25 years of experience in the corporate and biotechnology sectors including with Deutsche Life Science, Revotar Biopharmaceuticals AG, Medical Enzymes AG and Allianz. Mr. Voigt has also worked for German investment bank, net.IPO.AG, in the area of business development and German securities offerings, and was an investment manager for a midsize healthcare venture capital fund. He has a Master’s Degree in Business Administration from the Freie Universität of Berlin, and is a member of the investment committee for an Australian venture capital firm as well as the judging panel of Germany’s largest business plan competition.

Frédéric Triebel, M.D., Ph.D., founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as the Company’s Chief Medical Officer (CMO) and Chief Scientific Officer (CSO) following the acquisition of Immutep S.A in December 2014. In April 2023, he ceased his CMO role to foremost focus on his responsibilities as CSO and as a member of Immutep’s Board of Directors.

Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and in subsequent research identified the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.

First trained as a clinical haematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 156 publications and 59 patents.

Ms. Miller joined Immutep as General Counsel and Company Secretary in October 2012 and was promoted to the role of Chief Operating Officer in November 2016. She has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She has a Combined Bachelor of Laws (Honours) and Bachelor of Commerce, Accounting and Finance (double major) from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.

Mr. Mueller, MSc BBA, has worked in the field of clinical development of oncology drugs for nearly two decades and joined Immutep in 2016. He brings broad expertise in the clinical development and regulatory field. Mr. Mueller has successfully led multiple clinical studies, cross-functional teams and multiple scientific advice meetings with competent regulatory authorities around the world. After completing his Master of Science in Biotechnology at the Technical University Berlin, he joined Medical Enzymes AG where he focused on developing therapeutic enzymes for the treatment of cancer. Subsequently, Mr. Mueller worked with Ganymed Pharmaceuticals AG in developing ideal monoclonal antibodies in the field of immuno-oncology. While there he was responsible for the clinical program for its lead antibody zolbetuximab, its core asset that led to a $1.2 billion USD acquisition by Astellas in 2016.

Stephan Winckels M.D., Ph.D., has over 15 years of experience in oncology drug development. He has contributed to more than 40 Phase I-III cancer trials in a wide variety of solid tumors and hematological malignancies. Until 2023 Stephan headed the Medical Affairs group and Oncology Medical Team at Allucent (formerly SMS-oncology), a mid-size full-service CRO. He also held medical positions within the oncology therapeutic area at Wyeth Research (now Pfizer), Boehringer Ingelheim and Genmab.

Stephan obtained his Doctor of Medicine degree at Maastricht University in The Netherlands. He holds a PhD in Medical Physiology from Utrecht University, The Netherlands. He is a member of the European Society for Medical Oncology.

Dr. Jacoby joined Immutep in 2015 with more than 15 years’ experience in the biotech industry. Prior to her current role, she held various positions at pre-clinical and clinical-stage pharmaceutical companies, where she gained comprehensive experience in protein expression and purification as well as in analytical and preclinical development.

As Head Biochemist and Head of Manufacturing at different European biotech companies, she developed and supervised manufacturing processes conducted according to “Good Manufacturing Practice” (GMP) of biologicals and small molecules in interaction with Contract Manufacturing Organisations ensuring the supply of clinical trials up to Phase II. In parallel Dr. Jacoby was acting as an independent Medical Writer supporting companies in regulatory interactions for clinical trial applications.

Dr. Jacoby has a Master degree in Biochemistry and completed her PhD at the Institute for Biotechnology of the Martin-Luther-University of Halle-Wittenberg, Germany.

Dr. Flinn is an Australian Patent Attorney with more than 20 years of professional experience in building and managing IP portfolios, and joined Immutep in April 2017. He has worked extensively in both private practice and corporate patent practice, and prior to joining Immutep worked for GSK for seven years as Senior Patent Counsel where he managed the global patent portfolio of GSK’s dermatology business unit. He has also worked for two US-based pharmaceutical companies, a major Australian retailer, and a Melbourne based Patent Attorney firm. Prior to training and qualifying as a Patent Attorney, Dr. Flinn completed doctoral studies in peptide chemistry and structural biology at the University of Melbourne.

Mr. Fang joined Immutep in March 2018. He was previously Group Finance Manager at Kazia Therapeutics Limited, which is an ASX and NASDAQ dual listed biotechnology company developing oncology drugs.

After completion of his Master of Professional Accounting degree, Mr. Fang started his career as Auditor at PricewaterhouseCoopers (PwC) in China. He has over 12 years’ accounting and auditing experience across various industries including biotechnology, manufacturing and healthcare.

Mr. Fang has Master of Professional Accounting degree from Western Sydney University and Master of Commerce degree in Information System and Technology from Macquarie University. He is a member of CPA Australia.

Dr. Howard is an Australian scientist, executive manager, and entrepreneur; he was the overall winner of the 2014 Advance Global Australian Award for his global impact on the biotechnology field and green chemistry. He is a pioneer in the field of molecular parasitology and in leading the commercialisation of one of the most important methods used widely today in molecular biology today called “DNA Shuffling“ or “Molecular Breeding.” He is an inventor of five patents and has over 150 scientific publications.

After earning his Ph.D. in biochemistry from the University of Melbourne, Dr. Howard held positions at a number of leading research laboratories around the world, including the Immunoparasitology Laboratory at the Walter & Eliza Hall Institute in Melbourne and the National Institutes of Health in Bethesda, Maryland, where he became a tenured investigator. In industry, Dr. Howard worked at Schering-Plough’s DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California; was the President and Scientific Director of Affymax, Inc.; worked at GSK after their purchase of Affymax; and was the co-founder and CEO of Maxygen, Inc. after its spin-out of Affymax-GlaxoWellcome.

As Maxygen’s CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising a total of US $260 million in capital. Under Dr. Howard, Maxygen successfully developed and partnered dozens of technology applications and products, including novel protein pharmaceuticals. After leaving Maxygen in 2008, Dr. Howard started the CleanTech company Oakbio, Inc. and remains involved in a number of other innovative biotechnology companies in the USA and Australia. Dr. Howard is also currently Executive Chairman of NeuClone Pty Ltd and was a Director of Circadian Technologies Ltd from 2013 to 2015.

Mr. Voigt has served as CEO and Executive Director of Immutep since July 2014. He has over 25 years of experience in the corporate and biotechnology sectors including with Deutsche Life Science, Revotar Biopharmaceuticals AG, Medical Enzymes AG and Allianz. Mr. Voigt has also worked for German investment bank, net.IPO.AG, in the area of business development and German securities offerings, and was an investment manager for a midsize healthcare venture capital fund. He has a Master’s Degree in Business Administration from the Freie Universität of Berlin, and is a member of the investment committee for an Australian venture capital firm as well as the judging panel of Germany’s largest business plan competition.

Pete Meyers has been a Non-Executive Director of Immutep since February 12, 2014, and was appointed as Non-Executive Deputy Chairman on November 17, 2017. He was the Chief Financial Officer of Slayback Pharma LLC, a KKR portfolio company, until Slayback was sold to Azurity Pharmaceuticals, Inc. Prior to joining Slayback, Mr. Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation.

Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc.

Mr. Meyers also serves on the Board of Yamo Pharmaceuticals LLC. He is the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc., and he is also the Vice Chairman of East End Hospice, Inc. He earned a Bachelor of Science degree in Finance from Boston College and a Master of Business Administration degree from Columbia Business School.

Frédéric Triebel, M.D., Ph.D., founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as the Company’s Chief Medical Officer (CMO) and Chief Scientific Officer (CSO) following the acquisition of Immutep S.A in December 2014. In April 2023, he ceased his CMO role to foremost focus on his responsibilities as CSO and as a member of Immutep’s Board of Directors.

Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and in subsequent research identified the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.

First trained as a clinical haematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 156 publications and 59 patents.

Lis Boyce is a senior corporate lawyer with over 30 years’ experience including capital raisings, strategic collaborations, corporate governance and mergers & acquisitions. She is a partner in Piper Alderman’s corporate team, and co-chairs the firm’s Life Sciences & Healthcare focus group.

Lis’s strong focus on Life Sciences is reflected in her appointment as deputy chair of AusBiotech’s AusMedtech Advisory Group, and as a member of AusBiotech’s Leadership Committee for NSW.

Lis is a Graduate of the Australian Institute of Company Directors and a Fellow of the Governance Institute of Australia.